NEW YORK (GenomeWeb) – Indian oncology company HealthCare Global Enterprises said yesterday its Triesta Sciences unit and Strand Life Sciences have partnered to create a new tumor profiling genomics center.
The Strand-Triesta Center for Cancer Genomics will be located in Bangalore, where both of the partners are based, and it will provide sequencing-based genomic testing to help oncologists make cancer treatment decisions. The center will provide HCG's patients with access to Strand's genomic tests for cancer and other germline conditions, HCG Founder and Chairman B.S. Ajaikumar said in a statement.
HCG said it will adopt the Strand-Triesta center's testing as its new "standard-of-care," and expects that using next-generation sequencing to profile tumors will improve the effectiveness of and response rates for targeted chemotherapy and radiation treatments. These tests also may be used to detect hereditary risk in patients' family members, HCG said.
Strand, a portfolio company of San Francisco's Biomark Capital Partners, has three clinical and research labs in Bangalore. Triesta provides a range of lab and research services for oncology diagnostics, as well as biomarker and translational research.